Search

Displaying results 751 - 760 of 10000 in total
  1. Drug

    Etoricoxib

    go.drugbank.com/drugs/DB01628
    ApprovedInvestigationalWithdrawn

    It is approved in more than 60 countries worldwide but not in the US. … Etoricoxib is a new COX-2 selective inhibitor.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  2. Drug

    Brinzolamide

    go.drugbank.com/drugs/DB01194
    Approved

    [A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate. … Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.

  3. Drug

    Lisinopril

    go.drugbank.com/drugs/DB00722
    ApprovedInvestigational

    [L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. … [A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.

    Mixtures: Nu-lisinopril/hctz, Nu-lisinopril/hctzSynonyms: [N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, (S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline
  4. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963] … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

  5. Drug

    Anethole trithione

    go.drugbank.com/drugs/DB13853
    Approved

    appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by … Unfortunately, many of the specific mechanisms of action to these activities have yet to be formally elucidated, which means that while studies are ongoing, ATT itself is not necessarily formally indicated

  6. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

  7. Drug

    Tamsulosin

    go.drugbank.com/drugs/DB00706
    ApprovedInvestigational

    [A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]

    Products: Nb-tamsulosin CR
  8. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023.

  9. Drug

    Mecasermin rinfabate

    go.drugbank.com/drugs/DB14751
    ApprovedInvestigational

    Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent

  10. Drug

    Stem bromelain

    go.drugbank.com/drugs/DB12249
    Approved

    are currently not properly understood. … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects